USPTO serial 90534213
2G UNIC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 8, 2022
- Examiner
- CASE, LEIGH CAROLINE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with 2G UNIC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Julianne Abelman
Julianne Abelman Womble Bond Dickinson (US) LLP950 3rd Avenue, Suite 2400New York, NY 10022UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical and biological products, namely, reagents for use in the production of polypeptides and monoclonal antibodies for use in the field of in vitro scientific research; Reagents for non-medical use, namely, for scientific research in the field of recombinant DNA technology; Chemical, biochemical and biological products for non-medical use, namely, reagents for scientific and medical research use, and for use in manufacturing in the field of recombinant DNA technology; Proteins for use in the field of recombinant DNA technology, namely, proteins for use in recombinant DNA technology manufacturing not for medical use | ACTIVE | — |
| 005 | Biological products for medical use, namely, reagents for medical use with recombinant DNA technology for the purpose of allowing recombinant production of polypeptides and monoclonal antibodies; Reagents for medical use in the field of recombinant DNA technology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ProteoNic Biotechnology IP B.V.
- Other trademarks owned by ProteoNic Biotechnology IP B.V.
- Other trademarks owned by ProteoNic Biotechnology IP B.V.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named 2G UNIC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 20, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 20, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 20, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 20, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 8, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 10, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 21, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 21, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 1, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 17, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 17, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 17, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 17, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 17, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 7, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 6, 2021 | ALIE | ASSIGNED TO LIE | — |
| Sep 29, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 27, 2021 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Sep 27, 2021 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Sep 27, 2021 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Sep 13, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| May 20, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 22, 2021 | NWAP | NEW APPLICATION ENTERED | — |